Reneo Pharmaceuticals Inc expected to post a loss of 10 cents a share - Earnings Preview

Onkure Therapeutics

06/08/2024 19:33

* Reneo Pharmaceuticals Inc  RPHM.OQ   RPHM.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 8 (estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Reneo Pharmaceuticals
Inc is
for a loss of 10 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Reneo
Pharmaceuticals Inc is $2.25​, above​ its last closing price
of $1.39. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.46       -0.44      -0.25     Beat    42.7
 Dec. 31 2024  -0.56       -0.58      -0.71     Missed  -22.9
 Jan. 1 0001   -0.57       -0.57      -0.57     Met     0.3​
 Jun. 30 2023  -0.50       -0.52      -0.65     Missed  -25.8
 ​​Mar.        -0.59       -0.60      -0.60     Met     0.7
 31 2023                                                
 Dec. 31 2022              -0.60      -0.56     Beat    6.8​
 Sep. 30 2022  -0.57       -0.57      -0.53     Beat    7.3
 Jun. 30 2022  -0.58       -0.58      -0.50     Beat    14.1
 This summary was machine generated August 6 at 18:33 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)